Literature DB >> 26805411

Free thyroxine levels are associated with cognitive changes in individuals with a first episode of psychosis: A prospective 1-year follow-up study.

J Labad1, J D Barbero2, A Gutiérrez-Zotes3, I Montalvo2, M Creus3, Á Cabezas3, M Solé3, M J Algora3, G Garcia-Parés4, E Vilella3.   

Abstract

The results of previous cross-sectional studies suggest that free thyroxine (FT4) levels are associated with cognitive abilities (particularly attention/vigilance) during the early stages of psychosis. We aimed to explore whether hypothalamic-pituitary-thyroid hormones predict cognitive changes in a 1-year longitudinal study following first episodes of psychosis (FEP). We studied 36 FEP patients and a control group of 50 healthy subjects (HS). Plasma levels of thyroid-stimulating hormone (TSH) and FT4 were measured. Cognitive assessment was performed with the MATRICS Cognitive Consensus Cognitive Battery (MCCB). FEP patients were assessed twice (baseline and after 1year), whereas HS were assessed only once. We compared cognitive changes at 1year between three groups based on baseline FT4 levels: 1) lowest quartile (Q1, FT4<1.16ng/dL); 2) medium quartiles (Q2-Q3, FT4 1.16-1.54ng/dL); and 3) highest quartile (Q4, FT4>1.54ng/dL). No differences in TSH or FT4 levels were found between HS and FEP patients. All participants had FT4 levels within the normal range. HS outperformed FEP patients in all cognitive tasks. In relation to the relationship between FT4 levels and cognitive changes, a U-shaped pattern was observed: FEP patients from the middle quartiles (Q2-Q3) improved in attention/vigilance, whereas both extreme quartiles (Q1 and Q4) showed a worsening in this cognitive domain over time. Patients with lower FT4 (Q1) showed poorer baseline attention; therefore, lower baseline FT4 levels predicted a poorer prognosis in terms of attention performance. Our study suggests that baseline FT4 levels are associated with changes in attention and vigilance performance over one year in FEP patients.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Attention; Cognition; Psychosis; Schizophrenia; Thyroid; Thyroxine

Mesh:

Substances:

Year:  2016        PMID: 26805411     DOI: 10.1016/j.schres.2016.01.036

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

Review 1.  Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.

Authors:  Meritxell Tost; José Antonio Monreal; Antonio Armario; Juan David Barbero; Jesús Cobo; Clemente García-Rizo; Miquel Bioque; Judith Usall; Elena Huerta-Ramos; Virginia Soria; Javier Labad
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

2.  Gland New Psychosis: New Onset Adult Psychosis with Suicidal Ideation and Attempt in the Setting of Thyroid Storm.

Authors:  Esteban Cota; Jacob Lentz
Journal:  Case Rep Psychiatry       Date:  2017-03-07

3.  Behavior in dogs with spontaneous hypothyroidism during treatment with levothyroxine.

Authors:  Alenka Hrovat; Tiny De Keuster; Hans S Kooistra; Luc Duchateau; Mark A Oyama; Kathelijne Peremans; Sylvie Daminet
Journal:  J Vet Intern Med       Date:  2018-11-30       Impact factor: 3.333

4.  Glycated Haemoglobin Is Associated With Poorer Cognitive Performance in Patients With Recent-Onset Psychosis.

Authors:  Itziar Montalvo; Alexandre González-Rodríguez; Ángel Cabezas; Alfonso Gutiérrez-Zotes; Montse Solé; Maria José Algora; Laura Ortega; Lourdes Martorell; Vanessa Sánchez-Gistau; Elisabet Vilella; Javier Labad
Journal:  Front Psychiatry       Date:  2020-05-25       Impact factor: 4.157

5.  Redefining the Cut-Off Ranges for TSH Based on the Clinical Picture, Results of Neuroimaging and Laboratory Tests in Unsupervised Cluster Analysis as Individualized Diagnosis of Early Schizophrenia.

Authors:  Natalia Śmierciak; Marta Szwajca; Tadeusz J Popiela; Amira Bryll; Paulina Karcz; Paulina Donicz; Aleksander Turek; Wirginia Krzyściak; Maciej Pilecki
Journal:  J Pers Med       Date:  2022-02-09

6.  A Role for the Transcription Factor Nk2 Homeobox 1 in Schizophrenia: Convergent Evidence from Animal and Human Studies.

Authors:  Eva A Malt; Katalin Juhasz; Ulrik F Malt; Thomas Naumann
Journal:  Front Behav Neurosci       Date:  2016-03-30       Impact factor: 3.558

7.  Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: A Pilot Randomized Clinical Trial.

Authors:  Francesc Estrada; Josep Maria Crosas; Maribel Ahuir; Sara Pérez-Muñoz; Wanda Zabala; Raquel Aguayo; Juan David Barbero; Itziar Montalvo; Meritxell Tost; Laura Llauradó; Armand Guardia; Diego Palao; José Antonio Monreal; Javier Labad
Journal:  Front Psychiatry       Date:  2020-07-07       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.